Liver-Disease Opioid Study Used a Composite High-Risk Prescribing Definition

A chronic-liver-disease cohort combined high opioid dose and benzodiazepine co-prescribing under one risk label.

What the source reports

Among 12,425 patients, nearly half received an opioid over one year. Seventeen percent of opioid recipients met the study’s high-risk definition: a high morphine-equivalent dose or a concurrent benzodiazepine prescription. The authors examined demographic and clinical factors associated with prescribing patterns.

Limits of the evidence

This retrospective single-center study characterized prescriptions rather than proving ingestion or an adverse drug event. A composite category cannot be read as the prevalence of benzodiazepine co-use alone. Liver disease severity and pain indications complicate comparisons.

Implications for forensic review

For a toxicology opinion, identify which component placed a patient in a risk category. Co-prescription is a reason to investigate timing and overlap; it does not establish simultaneous exposure or the cause of altered consciousness. Actual administration and clinical records are needed.

Source and related reading

Source reviewed: Characteristics of opioid prescribing to outpatients with chronic liver diseases A call for action (PMC8682904). This article summarizes the supplied paper; forensic applications above are interpretive analysis.

Related reading: Replacing a Benzodiazepine With Another Sedative Does Not Automatically Remove Opioid Interaction Risk; Opioid Co-Use Changed the Mortality Comparison for Benzodiazepine Hypnotics in Older Adults.